about
A review of the methods used to define glucocorticoid exposure and risk attribution when investigating the risk of fracture in a rheumatoid arthritis populationPatient-reported outcomes as end points in clinical trials in rheumatoid arthritisUnresolved questions in rheumatology: motion for debate: the data support evidence-based management recommendations for cardiovascular disease in rheumatoid arthritisPatient Perspectives on Sharing Anonymized Personal Health Data Using a Digital System for Dynamic Consent and Research Feedback: A Qualitative StudyDynamic consent: a possible solution to improve patient confidence and trust in how electronic patient records are used in medical researchPredictors of distress in female breast cancer survivors: a systematic review.Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers.Influenza and Pneumococcal Vaccination Uptake in Patients with Rheumatoid Arthritis Treated with Immunosuppressive Therapy in the UK: A Retrospective Cohort Study Using Data from the Clinical Practice Research Datalink.Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.Cloudy with a Chance of Pain: Engagement and Subsequent Attrition of Daily Data Entry in a Smartphone Pilot Study Tracking Weather, Disease Severity, and Physical Activity in Patients With Rheumatoid Arthritis.Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community.EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid ArthritisDrug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics RegisterA comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesNo evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics RegisterInfluence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaRisk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et alThe association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analysesModelling and extraction of variability in free-text medication prescriptions from an anonymised primary care electronic medical record research database.What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.Does early rheumatoid arthritis exist?Problem list completeness in electronic health records: A multi-site study and assessment of success factors.Defining Disease Phenotypes in Primary Care Electronic Health Records by a Machine Learning Approach: A Case Study in Identifying Rheumatoid Arthritis.The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics RegisterImmediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysisThe Association between Systemic Glucocorticoid Use and the Risk of Cataract and Glaucoma in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general populationHalf of U.K. patients with rheumatoid arthritis are prescribed oral glucocorticoid therapy in primary care: a retrospective drug utilisation study.Who Self-Weighs and What Do They Gain From It? A Retrospective Comparison Between Smart Scale Users and the General Population in England.Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank.Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.Demographic and disease-related predictors of abnormal lung function in patients with established inflammatory polyarthritis and a comparison with the general population.Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis
P50
Q26748556-03C7CEA0-8FA0-4A7B-8F64-1BCB1147530EQ26778271-8CC4A539-796C-4421-A9F8-6455D22FC850Q26822912-75E5E94C-1752-4F60-8CA6-70DD533665E4Q28603520-440A604F-3450-4C10-B41B-0AD2AFC992C6Q28650413-088CA971-F55C-4A23-A250-79C5BBC432E8Q30234332-C044DE5F-5205-477C-8753-9C6692AF6BB8Q30936806-BBCA2A50-B467-459B-A3BC-538EF4EF2747Q31081624-78E28E11-F7F6-4E57-9588-D30D3750E494Q31123685-B1D3B1C6-7396-4E47-BB46-92053C324A65Q33453672-43C83EAA-D702-4661-B8EF-F3945D7B1BADQ33552640-F3421613-28D8-4468-8AC0-1EBEC1638AEAQ33595690-A7240DAE-160E-47A6-AE4F-CE35A1471A99Q33731716-70460582-4065-4DDB-A22A-AEBEF7D589F2Q34081925-89E963D3-31A3-49BF-A4EB-A9112AAC2CEAQ34110060-A18245CE-8ABD-4183-9356-482D6838C4B8Q34216770-040F647C-F6C4-4C38-A39A-4498BFE7BF66Q34699641-C23F627F-2039-40F8-B6FD-5ECCD77244D9Q34891374-8F2EC38F-B622-416A-86F7-284B55A708CFQ34905686-19826771-29C0-4163-9AAF-F1BFDE027AC6Q35018415-F080BD0D-A0BF-4C9A-A35C-A0B92D96194DQ35605468-EAE5C85D-0569-427E-81EC-76B2801B68BBQ35605656-92730276-8014-448E-8E61-0FD5875BA5FEQ35617753-1336C7C9-19DC-45FF-B2E8-4BBD0BD270C7Q35918557-0FF6575B-0F74-4AF9-A721-197B02946CC9Q35954625-FEFC9B37-964F-4021-8EAB-3F838BB7F0BFQ35978919-26582F61-60D8-4C77-9210-F6539D9A17E3Q35995382-9C08CBB1-4F13-4DCE-B504-17B997C1A23CQ36004938-B2922732-AB7D-45C2-8ECF-7D4044174F7DQ36020193-9113134C-119D-47A3-BCBC-E38A8B01BB43Q36033348-FA9C74D6-2C4A-4129-981C-8968CF575DE1Q36193029-C7E0CFC2-C93D-4761-A198-85A18CEB672CQ36464357-796BFC4A-9A31-4824-B578-87DB1B207E5AQ36477420-5530FF15-ECEB-415B-90E5-C477C7F69FACQ36548037-B93F7845-BDE5-4A2C-A2F0-C0D5233E1282Q36675167-0C777B25-2A16-473A-B0B4-42AF792B3E33Q36679750-3150B6D2-B041-4F3B-A0FB-A9118256763CQ36725347-C740582D-9B66-4D73-9AD5-614AC5E0E0EBQ37020532-4796E5EF-F9B0-4536-BDF4-B6E9285DBD40Q37130290-EB630617-AF4A-4969-A1F3-6EB53ACA9F0CQ37169479-73803FB7-343F-4652-AF3E-AC43F889560C
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
William Dixon
@ast
William Dixon
@en
William Dixon
@es
William Dixon
@nl
William Dixon
@sl
Уильям Диксон
@ru
type
label
William Dixon
@ast
William Dixon
@en
William Dixon
@es
William Dixon
@nl
William Dixon
@sl
Уильям Диксон
@ru
prefLabel
William Dixon
@ast
William Dixon
@en
William Dixon
@es
William Dixon
@nl
William Dixon
@sl
Уильям Диксон
@ru
P214
P244
P106
P1153
8935830000
P21
P214
P244
no2012028462
P2456
P31
P496
0000-0001-5881-4857
P734
P7859
lccn-no2012028462